Connect Biopharma Holdings Ltd ADR (CNTB) Stock Price, Quote & News

Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquarte...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1040

Website: www.connectbiopharm.com

Address:

3580 CARMEL MOUNTAIN ROAD, SUITE 200, San Diego, United States

VolcanicTrades Sep. 4 at 2:46 PM

$CNTB

0 · Reply

mikeywo Sep. 4 at 10:34 AM

$CNTB once ph2 data is out in the spring of 26 Barry will partner up with a large pharma or sell the company for a nice premium. He has a solid record for getting deals done and I believe he thinks this is one of the best assets he’s ever had under his control. If the data comes in as expected this is a billion dollar asset at a minimum.

0 · Reply

Motorhhead Sep. 4 at 9:48 AM

$CNTB uh huh

0 · Reply

Motorhhead Sep. 4 at 9:48 AM

$CNTB

0 · Reply

giancachimi Sep. 4 at 7:40 AM

$TC $CNTB $UUU $BRIA $SOGP

0 · Reply

fairytaleresearch Sep. 4 at 7:00 AM

$TC: unreal low float $CNTB: canceled ADRs, conference catalysh $UUU: Dividend and yet not that much appreciated

0 · Reply

beppels Sep. 4 at 6:51 AM

$TC BEPPELS WL 04.09.: - $TC, 13.2 $, with China mania it will be found, 110 k float, smallest in the market, swinging for 20-30 $! ✅ - $CNTB, 1.99 $, 12.5 mln float, switched adr s to commons, Cantor Healthcare Conference in ah, hit 2.77 $ high yesterday! ✅ - $UUU, 6.3 $, 1.8 mln float, 1 $ cash dividend, similar stocks like $BRIA or $SOGP went wild with higher floats, lot of room for $UUU to catch up! ✅ 👀 🔥 👀

0 · Reply

StockScanners Sep. 4 at 3:34 AM

$CNTB reached 2.75

0 · Reply

oldwisetrader Sep. 3 at 7:26 PM

$CNTB listening to Cantor conference , CEO speaking giving the story

0 · Reply

VolcanicTrades Sep. 3 at 6:55 PM

$CNTB still zero

1 · Reply

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 3, 2025, 8:00 AM EDT - 2 days ago

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

Aug 27, 2025, 9:00 AM EDT - 8 days ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

Aug 14, 2025, 8:00 AM EDT - 22 days ago

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Aug 13, 2025, 9:00 AM EDT - 22 days ago

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 9:00 AM EDT - 6 weeks ago

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Jul 21, 2025, 9:00 AM EDT - 6 weeks ago

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Jul 18, 2025, 9:00 AM EDT - 6 weeks ago

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Jul 17, 2025, 9:00 AM EDT - 7 weeks ago

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 13, 2025, 9:00 AM EDT - 2 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 3, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

May 28, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

May 20, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

May 15, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

May 13, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Apr 24, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Apr 1, 2025, 9:00 AM EDT - 5 months ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Mar 31, 2025, 4:05 PM EDT - 5 months ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Mar 31, 2025, 9:00 AM EDT - 5 months ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Mar 28, 2025, 4:05 PM EDT - 5 months ago

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 3, 2025, 8:00 AM EST - 6 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 11 months ago

Attovia Therapeutics Appoints Chief Financial Officer

Oct 9, 2024, 3:55 PM EDT - 11 months ago

CNTB Stock Dips Amid Biotech Sector Volatility

Oct 2, 2024, 4:14 PM EDT - 1 year ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Jun 12, 2024, 6:03 PM EDT - 1 year ago

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2024, 4:15 PM EDT - 1 year ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

May 22, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 7, 2024, 6:30 AM EDT - 1 year ago

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 12, 2024, 4:30 PM EST - 1 year ago

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Dec 12, 2023, 6:00 AM EST - 1 year ago

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Dec 11, 2023, 4:05 PM EST - 1 year ago

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Nov 21, 2023, 6:03 AM EST - 1 year ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Nov 21, 2023, 6:00 AM EST - 1 year ago

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Nov 20, 2023, 4:41 PM EST - 1 year ago

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Sep 12, 2023, 4:15 PM EDT - 2 years ago

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Sep 12, 2023, 6:00 AM EDT - 2 years ago

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Aug 24, 2023, 6:21 PM EDT - 2 years ago

Connect Biopharma to Participate in Upcoming September Investor Conferences

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

Jun 1, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Apr 11, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

Mar 18, 2023, 2:40 PM EDT - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Mar 17, 2023, 4:38 PM EDT - 2 years ago

Connect Biopharma stock up more than 40% after trial data

Mar 17, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Mar 6, 2023, 8:15 AM EST - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

VolcanicTrades Sep. 4 at 2:46 PM

$CNTB

0 · Reply

mikeywo Sep. 4 at 10:34 AM

0 · Reply

Motorhhead Sep. 4 at 9:48 AM

$CNTB uh huh

0 · Reply

Motorhhead Sep. 4 at 9:48 AM

$CNTB

0 · Reply

giancachimi Sep. 4 at 7:40 AM

$TC $CNTB $UUU $BRIA $SOGP

0 · Reply

fairytaleresearch Sep. 4 at 7:00 AM

$TC: unreal low float $CNTB: canceled ADRs, conference catalysh $UUU: Dividend and yet not that much appreciated

0 · Reply

beppels Sep. 4 at 6:51 AM

0 · Reply

StockScanners Sep. 4 at 3:34 AM

$CNTB reached 2.75

0 · Reply

oldwisetrader Sep. 3 at 7:26 PM

$CNTB listening to Cantor conference , CEO speaking giving the story

0 · Reply

VolcanicTrades Sep. 3 at 6:55 PM

$CNTB still zero

1 · Reply

oldwisetrader Sep. 3 at 6:50 PM

$CNTB I’ve seen a few of these elimination of ADR’s in my days ,,, typically funds who couldn’t own adrs come in the next few days after converting ,, let’s hope hope as with this stock about 100k in volume can send it to the moon and get the party started

0 · Reply

VolcanicTrades Sep. 3 at 6:32 PM

$CNTB

0 · Reply

VolcanicTrades Sep. 3 at 4:51 PM

$CNTB added some. Looks like it setting up to pop this afternoon.

0 · Reply

oldwisetrader Sep. 3 at 2:43 PM

$CNTB entering 1.85 for multi week swing

0 · Reply

mikeywo Sep. 3 at 2:20 PM

$CNTB I thought switching over was suppose to be a positive

0 · Reply

Diplo Sep. 3 at 1:45 PM

$CNTB damnit

0 · Reply

Fire_Truck Sep. 3 at 1:30 PM

$CNTB Currently in phase 3 trial. Probably going to have to dilute soon, hence why you're seeing commercials to draw attention to the stock.

2 · Reply

oldwisetrader Sep. 3 at 12:24 PM

$CNTB stock hits my radar scanner this morning , and just saw ad on cnbc this am,, the universe might be speaking ,, I’m not one to buy a Stock up 15 percent premarket , but watching closely for now

0 · Reply

beppels Sep. 3 at 12:10 PM

$CNTB https://www.stocktitan.net/news/CNTB/connect-biopharma-completes-termination-of-its-american-depositary-ol0rct537pxn.html $TC, 110 k float

0 · Reply

oldwisetrader Sep. 3 at 12:06 PM

$CNTB any kind of volume and this jumps above $3

0 · Reply

fairytaleresearch Sep. 3 at 12:00 PM

$CNTB Very interesting set-up and great find by @beppels Cancelled ADRs and changed to commons. Happened twice this year ($BQ 2->10 and $MAAS 3->15) 0 shares to borrow!

0 · Reply

Ezy_Money_083 Sep. 3 at 11:38 AM

@MS_Tammy $CNTB News?

3 · Reply

Market Cap	110.89M
Revenue (ttm)	26.03M
Net Income (ttm)	-15.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60.05%
Debt to Equity Ratio	0.00

Volume	203,500
Avg Vol	197,092
Day's Range	N/A - N/A
Shares Out	55.72M
Stochastic %K	26%
Beta	-0.09
Analysts	Strong Sell
Price Target	$6.83